DYN Q1 2017 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$175M+4.2% YoY

Gross Profit

-$582M-332.6% margin

Operating Income

-$49M-28.0% margin

Net Income

$597M341.1% margin

EPS (Diluted)

$3.69

QoQ Revenue Growth

-77.9%

Cash Flow

Operating Cash Flow

$149M

Free Cash Flow

$118M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$13.1B

Total Liabilities

$10.7B

Stockholders' Equity

$2.4B

Cash & Equivalents

$467M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$175M	$168M	+4.2%
Gross Profit	-$582M	-$377M	-54.4%
Operating Income	-$49M	$145M	-133.8%
Net Income	$597M	-$10M	+6070.0%